AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27701170 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (intravenous, 2 g per day for 4 days)
Number of subjects: 2538
Study 23995395 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (3 months after acute phase)
Number of subjects: 35
Study 23995395 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-herpetic neuralgia patients
Number of subjects: 35
Study 23995395 — intervention group
Group type: COMPARATOR
Intervention: Antiviral therapy
Number of subjects: 35
Study 23995395 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal free nerve endings
Number of subjects: 35
Study 23104856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) 4g/d supplying 1,600mg/d eicosapentaenoic acid and 800mg/d docosahexaenoic acid
Number of subjects: 40
Study 23104856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) 4g/d
Number of subjects: 40
Study 20479282 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-gene model including 4 functional pathways (cell cycle, apoptosis, macrophage activation, and interferon regulatory factor 4)
Number of subjects: 282
Study 20479282 — intervention group
Group type: EXPERIMENTAL
Intervention: Final predictive model combining stage IV
Number of subjects: 282
Study 19020155 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (three bolus of 1 microg x kg(‐1))
Number of subjects: 90
Study 19020155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (infusion of 15 microg x kg(‐1) x min(‐1))
Number of subjects: 90
Study 19020155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine and fentanyl (infusion of 15 microg x kg(‐1) x min(‐1) ketamine plus three bolus of 1 microg x kg(‐1) fentanyl)
Number of subjects: 90
Study 19020155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (one bolus of 8 mg)
Number of subjects: 90
Study 19020155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam and fentanyl (one bolus of 8 mg lornoxicam plus three bolus of 1 microg x kg(‐1) fentanyl)
Number of subjects: 90
Study 15750152 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FET PET
Number of subjects: 38
Study 15750152 — intervention group
Group type: COMPARATOR
Intervention: 18F‐FDG PET
Number of subjects: 38
Study 15750152 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of 18F‐FET PET in head-neck carcinomas
Number of subjects: 38
Study 12036083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1 g/day
Number of subjects: 620
Study 12036083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 5 g/day
Number of subjects: 620
Study 12036083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 10 g/day
Number of subjects: 620
Study 12036083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 10602891 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU/LMS therapy
Number of subjects: 38
Study 7549345 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol in Gelrite administered once daily (TG)
Number of subjects: 156
Study 7549345 — intervention group
Group type: COMPARATOR
Intervention: 0.25% timolol solution administered twice daily (TS)
Number of subjects: 156
Study 7549345 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol in Gelrite (TG)
Number of subjects: 156
Study 2202283 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsite alone
Number of subjects: 0
Study 2202283 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsite after application of bupivacaine
Number of subjects: 0
Study 2202283 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarlet ointment dressing alone
Number of subjects: 0
Study 2202283 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarlet ointment after bupivacaine
Number of subjects: 0
Study 2202283 — intervention group
Group type: COMPARATOR
Intervention: Opsite
Number of subjects: 0
Study 2202283 — intervention group
Group type: COMPARATOR
Intervention: Scarlet ointment
Number of subjects: 0
Study 6972732 — intervention group
Group type: EXPERIMENTAL
Intervention: nalidixic acid (NA), 1 g every 6 h for 7 days
Number of subjects: 135
Study 6972732 — intervention group
Group type: COMPARATOR
Intervention: trimethoprim/sulfamethoxazole (TMP/SMZ), 160/800 mg every 12 h for 10 days
Number of subjects: 135
Study 31661738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 1001
Study 31661738 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 1001
Study 31661738 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning Symbol
Number of subjects: 1001
Study 31661738 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating system (HSR)
Number of subjects: 1001
Study 31661738 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Intakes (RIs)
Number of subjects: 1001
Study 27432173 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopic decompression
Number of subjects: 2
Study 27432173 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 2
Study 25922451 — intervention group
Group type: EXPERIMENTAL
Intervention: Short metaphyseal fixation (SMF) stem
Number of subjects: 43
Study 25922451 — intervention group
Group type: COMPARATOR
Intervention: Standard-length tapered Synergy metaphyseal fixation stem
Number of subjects: 43
Study 25922451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 24103528 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation detection by DHPLC
Number of subjects: 127
Study 24103528 — intervention group
Group type: EXPERIMENTAL
Intervention: K-RAS mutation detection by direct sequencing
Number of subjects: 127
Study 21438171 — intervention group
Group type: EXPERIMENTAL
Intervention: eFlow® nebulizer (100 mg/ml tobramycin solution, 1.5 ml)
Number of subjects: 16
Study 21438171 — intervention group
Group type: COMPARATOR
Intervention: PARI LC PLUS® nebulizer (300 mg at 60 mg/ml tobramycin)
Number of subjects: 16
Study 21438171 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of delivery times
Number of subjects: 16
Study 21438171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerability of treatment
Number of subjects: 16
Study 19289727 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty calibration training (three two-hour training sessions)
Number of subjects: 12
Study 19289727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study 16167971 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg am and 20 mg pm for 7 days
Number of subjects: 35
Study 16167971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12800605 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan (60 mg/m2 on days 1 and 8) plus carboplatin (AUC 4.0 on day 1, every 28 days)
Number of subjects: 53
Study 12800605 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan (90 mg/m2 on days 1 and 8) plus carboplatin (AUC 2.0 on days 1 and 8, every 21 days)
Number of subjects: 53
Study 10233192 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg AM + Ranitidine 150 mg HS
Number of subjects: 20
Study 10233192 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.d. AC
Number of subjects: 20
Study 8554479 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk flexor and extensor endurance tests
Number of subjects: 190
Study 8554479 — intervention group
Group type: COMPARATOR
Intervention: New method for measuring lumbar lordosis
Number of subjects: 190
Study 1762809 — intervention group
Group type: COMPARATOR
Intervention: Conventional continuous stimulation (70 Hz)
Number of subjects: 27
Study 1762809 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst stimulation (90 msec trains of pulses, 100 Hz internal frequency, 2 Hz repetition)
Number of subjects: 27
Study 1762809 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-modulated stimulation (90 Hz to 55 Hz over 90 msec)
Number of subjects: 27
Study 6811217 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy (rifampicin, isoniazid, ethambutol until sensitivity tests completed, then isoniazid alone for four months)
Number of subjects: 168
Study 6811217 — intervention group
Group type: COMPARATOR
Intervention: Two-year chemotherapy scheme (rifampicin, isoniazid, ethambutol until culture conversion, then isoniazid alone for two years)
Number of subjects: 168
Study 31106835 — intervention group
Group type: EXPERIMENTAL
Intervention: cetuximab
Number of subjects: 14
Study 31106835 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 27964770 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and communication skills intervention (CCI)
Number of subjects: 201
Study 27964770 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 201
Study 25926350 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg Novaferon injected 3 times per week
Number of subjects: 108
Study 25926350 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg Novaferon injected twice per week
Number of subjects: 108
Study 25926350 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg Novaferon injected 3 times per week
Number of subjects: 108
Study 25926350 — intervention group
Group type: COMPARATOR
Intervention: Saline injected 3 times per week (placebo)
Number of subjects: 108
Study 23352226 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg
Number of subjects: 1030
Study 23352226 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 50/25 μg
Number of subjects: 1030
Study 23352226 — intervention group
Group type: EXPERIMENTAL
Intervention: VI 25 μg
Number of subjects: 1030
Study 21275961 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide + placebo
Number of subjects: 36
Study 21275961 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium + placebo
Number of subjects: 36
Study 21275961 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide + Magnesium
Number of subjects: 36
Study 21275961 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 36
Study 19864407 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 335
Study 17712588 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (mean dose 2.93 ± 0.75 mg per day, range 0.75 to 5 mg)
Number of subjects: 90
Study 17712588 — intervention group
Group type: COMPARATOR
Intervention: Control group (36 subjects, mean age 55.0 ± 12.8 years)
Number of subjects: 90
Study 17712588 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (mean dose 2.93 ± 0.75 mg per day)
Number of subjects: 90
Study 15856361 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily (n=12)
Number of subjects: 37
Study 15856361 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg twice weekly (n=11)
Number of subjects: 37
Study 15856361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=14)
Number of subjects: 37
Study 12424712 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (3 million units subcutaneously three times weekly) plus ribavirin (800 to 1,000 mg/d) for 12 months
Number of subjects: 54
Study 12424712 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b plus ribavirin
Number of subjects: 54
Study 10482176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariporide (HOE 642) 40 mg intravenous bolus prior to reperfusion
Number of subjects: 0
Study 10482176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7661176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 8
Study 7661176 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study 7661176 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (Control)
Number of subjects: 8
Study 1755159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid administered in complex with tyrosine catabolism cofactors (pyridoxal phosphate, ascorbic acid, iron ions)
Number of subjects: 0
Study 1755159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid
Number of subjects: 0
Study 1755159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid in complex with vitamins B1, B2, B5 (PP), B6 (pyridoxal phosphate), C
Number of subjects: 0
Study 1755159 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 7048246 — intervention group
Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 0
Study 7048246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31502886 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS + LMWH
Number of subjects: 93
Study 31502886 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS no LMWH
Number of subjects: 93
Study 31502886 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracotomy + LMWH
Number of subjects: 93
Study 31502886 — intervention group
Group type: COMPARATOR
Intervention: VATS patients
Number of subjects: 93
Study 31502886 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy patients
Number of subjects: 93
Study 28926857 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet with potassium supplementation (4.5 g/day, KCl)
Number of subjects: 45
Study 28926857 — intervention group
Group type: COMPARATOR
Intervention: High-salt diet
Number of subjects: 45
Study 28926857 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet to high-salt diet
Number of subjects: 45
Study 28926857 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet to potassium supplementation
Number of subjects: 45
Study 27160842 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT
Number of subjects: 485
Study 27160842 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 485
Study 25122430 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/d
Number of subjects: 1060
Study 22225997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored training of household heads about the proper use of LLITN and community network system
Number of subjects: 2612
Study 19281935 — intervention group
Group type: EXPERIMENTAL
Intervention: IV hydromorphone (0.0075 mg/kg)
Number of subjects: 194
Study 19281935 — intervention group
Group type: COMPARATOR
Intervention: IV morphine (0.05 mg/kg)
Number of subjects: 194
Study 17635381 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplementation
Number of subjects: 55
Study 17635381 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 55
Study 15140452 — intervention group
Group type: EXPERIMENTAL
Intervention: Integral checklist intervention
Number of subjects: 229
Study 15140452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no checklist)
Number of subjects: 229
Study 12216046 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water irrigation
Number of subjects: 46
Study 12216046 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 46
Study 9666826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 10
Study 9666826 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 10
Study 9666826 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 10
Study 9666826 — intervention group
Group type: COMPARATOR
Intervention: Bradykinin
Number of subjects: 10
Study 8590551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental distraction (SB + word puzzle)
Number of subjects: 30
Study 8590551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (SB + computer quiz)
Number of subjects: 30
Study 8590551 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious control of breathing (paced at SB rate)
Number of subjects: 30
Study 8590551 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous breathing)
Number of subjects: 30
Study 2667638 — intervention group
Group type: COMPARATOR
Intervention: minus lenses with full correction for continuous use (the reference group)
Number of subjects: 240
Study 2667638 — intervention group
Group type: EXPERIMENTAL
Intervention: minus lenses with full correction to be used for distant vision only
Number of subjects: 240
Study 2667638 — intervention group
Group type: EXPERIMENTAL
Intervention: bifocal lenses with +1.75 D addition
Number of subjects: 240
Study 821802 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed oral typhoid vaccine from the German Democratic Republic (GDR)
Number of subjects: 75083
Study 821802 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed oral typhoid vaccine from the German Federal Republic (GFR)
Number of subjects: 75083
Study 821802 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group for GDR vaccine)
Number of subjects: 75083
Study 821802 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group for GFR vaccine)
Number of subjects: 75083
Study 29509918 — intervention group
Group type: EXPERIMENTAL
Intervention: Unchanged L‐T4 dose
Number of subjects: 138
Study 29509918 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher L‐T4 dose
Number of subjects: 138
Study 29509918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower L‐T4 dose
Number of subjects: 138
Study 29509918 — intervention group
Group type: COMPARATOR
Intervention: All groups (Unchanged, Higher, Lower)
Number of subjects: 138
Study 26437957 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/daily
Number of subjects: 60
Study 26437957 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/daily
Number of subjects: 60
Study 26437957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25459793 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy affective expression
Number of subjects: 0
Study 25459793 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral affective expression
Number of subjects: 0
Study 25459793 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry affective expression
Number of subjects: 0
Study 22741474 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine decoction (supplementing qi and nourishing yin recipe)
Number of subjects: 106
Study 22741474 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (depogeston)
Number of subjects: 106
Study 22741474 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine decoction
Number of subjects: 106
Study 22741474 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine decoction and Medroxyprogesterone acetate
Number of subjects: 106
Study 20368909 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acid supplementation (EAAs) embedded in a 12-week rehabilitation program
Number of subjects: 28
Study 20368909 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) receiving the same program without supplementation
Number of subjects: 28
Study 18381508 — intervention group
Group type: EXPERIMENTAL
Intervention: School Nutrition Policy Initiative
Number of subjects: 1349
Study 18381508 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1349
Study 16044002 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous HAART
Number of subjects: 74
Study 16044002 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-guided treatment
Number of subjects: 74
Study 16044002 — intervention group
Group type: COMPARATOR
Intervention: Week-on-week-off treatment
Number of subjects: 74
Study 12633122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 94
Study 12633122 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 94
Study 10622646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 16
Study 10622646 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 16
Study 8620717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (four daily doses)
Number of subjects: 10
Study 8620717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo)
Number of subjects: 10
Study 1954354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Ara‐C (3 g/m2 IV over 1 h every 12 h eight times followed by 25 mg/m2 per day daunorubicin IV bolus for 2 days)
Number of subjects: 27
Study 1954354 — intervention group
Group type: COMPARATOR
Intervention: Conventional consolidation therapy (200 mg/m2 of behenoyl‐arabino‐furanosylcytosine for 7 days and 25 mg/m2 of daunorubicin for 2 to 3 days)
Number of subjects: 27
Study 6257941 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Number of subjects: 50
Study 6257941 — intervention group
Group type: COMPARATOR
Intervention: Control (no warfarin)
Number of subjects: 50
Study 29905630 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation (n = 4) for 5 minutes followed by continuous stimulation until lead removal on postoperative days 14 to 28.
Number of subjects: 7
Study 29905630 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation (n = 7) for 30 minutes after initial treatment.
Number of subjects: 7
Study 29905630 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous stimulation with active stimulation (n = 7).
Number of subjects: 7
Study 29905630 — intervention group
Group type: COMPARATOR
Intervention: Sham (n = 3) for 5 minutes followed by crossover to stimulation.
Number of subjects: 7
Study 29905630 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue analgesia with continuous popliteal nerve block (n = 7).
Number of subjects: 7
Study 27737774 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33°C)
Number of subjects: 54
Study 27737774 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia (36.8°C)
Number of subjects: 54
Study 24670156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetics use by women
Number of subjects: 0
Study 24670156 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-applied cosmetics by models
Number of subjects: 0
Study 22520518 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature management of 33°C
Number of subjects: 850
Study 22520518 — intervention group
Group type: COMPARATOR
Intervention: Target temperature management of 36°C
Number of subjects: 850
Study 20171597 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate therapy
Number of subjects: 28
Study 20171597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28